116
Participants
Start Date
May 15, 2023
Primary Completion Date
September 30, 2028
Study Completion Date
September 30, 2028
Debio 0123
Administered as capsules.
Temozolomide
Administered as capsules.
Radiotherapy
Administered in accordance with the local clinical practice and applicable Radiation Therapy Oncology Group (RTOG) or the European Organization for Research and Treatment of Cancer (EORTC) guidelines.
RECRUITING
New York University Langone Medical Center, New York
RECRUITING
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
NOT_YET_RECRUITING
Hospital Universitario Donostia, Donostia / San Sebastian
NOT_YET_RECRUITING
Hospital Universitario Donostia, San Sebastián
RECRUITING
Clinica Universidad de Navarra (CUN), Madrid
RECRUITING
South Texas Accelerated Research Therapeutics (START), Madrid
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
Clinica Universidad de Navarra (CUN), Pamplona
NOT_YET_RECRUITING
Hospital Clinico Universitario de Valencia, Valencia
RECRUITING
Northwestern Memorial Hospital, Chicago
RECRUITING
Baylor Scott & White Research Institute, Dallas
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
South Texas Accelerated Research Therapeutics (START), San Antonio
RECRUITING
Huntsman Cancer Institute, Salt Lake City
RECRUITING
Fred Hutchinson Cancer Research Center, Seattle
RECRUITING
Hospital Universitario Vall d'Hebron, Barcelona
RECRUITING
Universitaetsspital Zuerich, Zurich
Lead Sponsor
Debiopharm International SA
INDUSTRY